



MiMedx
GROUP

Innovations in Regenerative Biomaterials



Forward Looking Statement

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the market opportunity for the Company's products, the expected breakeven point, the expected revenue ramp, the timing of future product offerings and the revenues there from, and the timing of proposed regulatory submissions and approvals. These statements are based on current information and belief, and are not guarantees of future performance. Our ability to predict results, financial or otherwise, or the actual effect of future plans or strategies is inherently uncertain and actual results may differ from those predicted depending on a variety of factors. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company requires significant additional capital to survive and achieve its goals, which may be difficult or impossible to obtain; that the Company may not receive requisite regulatory clearances and/or approvals to be able to market a full range of products or that such clearances or approvals may be delayed; that the Company may not be able to establish an effective distribution system for its products in the U.S. or abroad; that the Company's products may not gain the anticipated acceptance in the marketplace or that acceptance may be delayed; the effects of competition; and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2010. By making these forward-looking statements, MiMedx Group, Inc. does not undertake to update those in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

Company Summary

- Publicly traded OTC:BB MDXG; Market Cap \approx \$90M
- Over 60 issued and pending patents
- Multi-Billion dollar market opportunity
- Experienced management team to manage rapid growth (www.thepetitgroup.com)
- Revenue growing at a rapid rate quarter over quarter in wound, spine and other markets, driven by amniotic membrane tissue
- Rapid growth in customer base, quarter over quarter, indicating market acceptance
- Approaching EBITDA Breakeven

Experienced Management Team

Parker H. "Pete" Petit

Chairman & CEO

Bill Taylor

President & COO

John Daniel

President, Surgical Biologics

Michael J. Senken

Chief Financial Officer

Donald E. Fetterolf, MD

Chief Medical Officer

Michael Carlton

VP, Global Sales

Frank Burrows

VP, Global Marketing

Roberta McCaw

General Counsel

Thornton Kuntz

VP, Human Resources & Administration



Soft Tissue Repair

HUMAN TISSUE-BASED TECHNOLOGIES (AMNION)

EpiFix®
(External)


AmnioFix®
(Internal)

MEDICAL DEVICE-BASED TECHNOLOGIES

CollaFix®
(Collagen Fiber)

HydroFix®
(PVA Hydrogel)

Large Market Opportunity



EpiFix™ AmnioFix™


- Transplanted, dehydrated human tissue
 - Membrane barrier & Injectable
 - Reduces scar tissue formation & inflammation
 - Non-immunogenic
 - Enhances wound healing
 - Combination of growth factors unique to placental tissues
- Room Temperature Storage, 5 year shelf Life
- FDA Regulated as Human Tissue under Sec.361, PHS Act (HCT/Ps)
 - Minimally manipulated
 - Homologous Use
 - **No 510(k) or PMA required**
- Significant Intellectual Property (Barrier to Entry)
 - Pending patents and trade secrets
- Secure Source of Supply
 - Multi-hospital currently & multi-state in 2012



Powder/
Injectable

Over 60,000 Amniotic Tissue Grafts Distributed

Ophthalmology



Treatment of pterygium and chemical burns.

Dental



Treatment of gingival recession defects

Wound Healing



Diabetic foot ulcer healed in 4 weeks

Spine/Ortho



AmnioFix Nerve Wrap on the Sciatic Nerve



- Chronic Wounds: diabetic foot ulcers, venous stasis ulcers, arterial ulcers, pressure ulcers
- Acute wounds: burns, plastic surgery, scar revision
- Near Term, Accelerated Ramp
- \$5.5B Market

- Tendon / Ligament Wrap
- Peripheral Nerve Wrap
- Spinal Surgery (fusions, laminectomies, disk replacements, dural repair)
- Near to Longer Term, Moderate Ramp
- \$3.4B Market

**Soft Tissue Repair:
Not simply dermis or epidermis repair!**

EpiFix® Attribute Matrix

TISSUE INDICATIONS & USES	EpiFix®	Apligraf®	Dermagraft®
Chronic Wound: Diabetic Foot Ulcer	✓	✓	✓
Chronic Wound: Venous Leg Ulcer	✓	✓	FAILED
Chronic Wound: Pressure Ulcer (bed sore)	✓		
Chronic Arterial Ulcers	✓		
Acute Wounds: Burns	✓		
Acute Wounds: Trauma	✓		
Acute Wounds: Surgical	✓		

EpiFix® Attribute Matrix

EASE OF USE:	EpiFix®	Apligraf®	Dermagraft®
Vulnerable Viable Cells	NO	Yes	Yes
Wide Temperature Range	0-38° C		
Frozen			√
Limited Temperature Range		20-23° C	(-80° C) ±10%
Shelf Life	5 Years	10 days	6 months
Shipping	Easy	Special (CO ₂)	Dry Ice
Multiple Sizes	√		
TREATMENT COST*:	EpiFix®	Apligraf®	Dermagraft®
Average Applications per Patient	1-2	3-5	4-8
Average Cost to Closure	\$3,890	\$8,000	\$11,200

*1 EpiFix: Value Based Purchasing for Wound Care White Paper; Donald Fetterolf, MD, MBA; ² Falanga V; Margolis D; Alvarez O; Auletta M; Maggiasomo F; Altman M; Jensen J; Sabolinski M; Hardin-Young and the Human Skin Equivalent Investigators Group "Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent." ArchDermatol. (134)3. 01-MAR-1998. pp 293-300. ³ Apligraf product promotional literature estimates of cost/reimbursements. 2010. ⁴ Apligraf product literature, "Rethink the Wound. Think Apligraf" 2010. John, T. "Human amniotic membrane transplantation: Past, present, and future." Ophthal Clin N Am. (16). 2003. pp 43-65. ⁵ Dermagraft product literature, describing treatments weekly for 8 applications.

Case Studies

EpiFix used AFTER other advanced treatments

Day - 0: post application of EpiFix



Day - 35: Healed



- DFU open for approximately 1.5 years
- Prior treatments; 8 wound VACs, 4 Apligraf, 1 Oasis, and 1 Graft Jacket.
- Two EpiFix grafts, an aggressive treatment plan but the progress in the words of Dr. Adams "Remarkable". Closure in 35 days!

EpiFix used BEFORE other advanced treatments

Day - 0: After debridement and prior to application of EpiFix



Day - 28: Healed



- 30% wound area reduction at 7 days
- Additional 15% area reduction at Day 14 and additional EpiFix graft was applied
- Wound closed at day 28
- At 3 months wound remains fully closed, patient walking with custom molded shoe

EpiFix® Product Reimbursement

Available	Payer	Office	Surgery Center	Hospital
Now	HPCS Q4100*	X	X	X
Jan 1 st 2012	CMS C-9366		X	X
Jan 1 st 2013 [†]	CMS Q-Code	X	X	X

*History of coverage: BCBS, Cigna, Humana and United.

† Based on positive CMS determination of coverage.

**HCPCS Level II Code Q4100 – Skin Substitute, not otherwise specified

- Reimbursement Hotline
 - Pre-authorization of benefit helpline
 - Dedicated reimbursement expert
 - Assists individual accounts with coding

Disruptive Technologies in Wound care

Past Disruptions

Mechanical
Multi Billion



1995

Vacuum Assist Closure

Growth Factor
\$300 million +



1998

Regranex®

Tissue Engineered Skin
\$600 Million +




1998

Apligraf®



2001

Dermagraft®



Dehydrated Amniotic Membrane & Powder Allograft is the most recent disruptive technology in wound healing

EpiFix™



AmnioFix



2011 Tissue Repair

VAC 1995 = <http://www.worldwidewounds.com/2001/may/Thomas/Vacuum-Assisted-Closure.html> , Apligraf 1998 = http://findarticles.com/p/articles/mi_m0EIN/is_1999_Nov_3/ai_57155480/, Regranex 1998 = <http://www.regranex.com/REGRANEX%20Gel%20Fact%20Sheet.php>, Dermagraft 2001 = http://global.smith-nephew.com/master/news_dermagraft_joint_ven_13349.htm

Next Six Months

EpiFix®

- First CMS C-Code in January 2012; currently reimbursed by major private health insurances
- Multiple retrospective case studies completed & in publication phase
- Multiple randomized control trials underway with completion estimated in 1st Quarter 2012
- Additional direct competitive studies to Apligraf® and Dermagraft® in 2012

AmnioFix®

- Full scale launch of AmnioFix® Injectable planned in the first quarter 2012

2012 Growth driven by CMS code, private pay reimbursement expansion and new product introductions

\$ millions



*Excludes share based compensation and one time items

Financial Highlights

2011

- Raised over \$10M to support growth
- Maintained tight controls over spending while adding critical sales and marketing resources in wound care and orthopedics
- Expanded manufacturing capacity
- End the year with \$4M+ in cash on the balance sheet

2012

- Adjusted EBITDA positive in Q1
- Gross Margins projected at 80%+ by Q4
- Planned staffing increases aligned with revenue growth

Investment Highlights

- Three complimentary technology platforms addressing large high growth markets including wound care and tissue regeneration
- More predictable REGULATORY profile compared to traditional device companies due to allograft platform offerings
- EXPERIENCED management team with proven track record of success in high growth healthcare businesses
- Strong PATENT portfolio creates significant barriers to entry
- PURION[®] processed allografts have clinical and cost advantages over competitors, including Advanced BioHealing's ("ABH") Dermagraft[®]
- Shire acquisition of ABH affirms revenue growth and value creation potential.
- Near term milestones for value creation:
 - Achieve adjusted EBITDA* breakeven
 - Continued Q over Q revenue growth
 - Completion of clinical studies in several critical areas
 - Train Healthcare providers on CMS C code for Medicare reimbursement

*excludes share based compensation



MiMedx
GROUP

Innovations in Regenerative Biomaterials

